Orexo sues Actavis and Teva over narcotic dependency treatment
Pharmaceutical company Orexo has filed a complaint against Actavis Elizabeth and Teva Pharmaceuticals for infringing its patents covering Zubsolv (buprenorphine and naloxone).
Zubsolv is used to treat opioid narcotic dependence and is covered by US patent numbers 9,259,421 and 8,940,330.
The case was filed on Wednesday, June 14, at the US District Court for the District of Delaware.
According to the complaint, Actavis submitted an amendment to an Abbreviated New Drug Application (ANDA) seeking approval from the Food and Drug Administration to bring a generic of Zubsolv to market.
The complaint further alleged that Teva had actively participated in activities related to the ANDA submission.
Orexo has asked the district court for a judgment in its favour, as well as a permanent injunction enjoining the defendants from bringing the generic drug to market.
It has also asked for costs of bringing the case to court.
Today’s news:
Biopharma must target unpopularity, says Allergan
Intellia granted China patent for CRISPR technology
General Court to hear drug competition cases
Fed Circuit invalidates diagnostics patents
J&J reveals obesity and 3D printing collaborations
Merck granted its first CRISPR patent in Australia
Did you enjoy reading this story? Sign up to our free newsletters and get stories like this sent straight to your inbox.
